DNLI
Price
$20.86
Change
-$0.23 (-1.09%)
Updated
Feb 9, 04:40 PM (EDT)
Capitalization
3.29B
21 days until earnings call
Intraday BUY SELL Signals
RLAY
Price
$8.86
Change
-$0.06 (-0.67%)
Updated
Feb 9, 11:22 AM (EDT)
Capitalization
1.55B
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs RLAY

Header iconDNLI vs RLAY Comparison
Open Charts DNLI vs RLAYBanner chart's image
Denali Therapeutics
Price$20.86
Change-$0.23 (-1.09%)
Volume$2.88K
Capitalization3.29B
Relay Therapeutics
Price$8.86
Change-$0.06 (-0.67%)
Volume$709
Capitalization1.55B
DNLI vs RLAY Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. RLAY commentary
Feb 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and RLAY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 09, 2026
Stock price -- (DNLI: $21.08 vs. RLAY: $8.92)
Brand notoriety: DNLI and RLAY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 95% vs. RLAY: 147%
Market capitalization -- DNLI: $3.29B vs. RLAY: $1.55B
DNLI [@Biotechnology] is valued at $3.29B. RLAY’s [@Biotechnology] market capitalization is $1.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRLAY’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RLAY’s FA Score: 1 green, 4 red.
According to our system of comparison, RLAY is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while RLAY’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • RLAY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than RLAY.

Price Growth

DNLI (@Biotechnology) experienced а -3.04% price change this week, while RLAY (@Biotechnology) price change was +16.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.15%. For the same industry, the average monthly price growth was -2.76%, and the average quarterly price growth was +26.50%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

RLAY is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (-1.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.29B) has a higher market cap than RLAY($1.55B). DNLI YTD gains are higher at: 27.680 vs. RLAY (5.437). RLAY has higher annual earnings (EBITDA): -322.8M vs. DNLI (-534.17M). DNLI has more cash in the bank: 848M vs. RLAY (596M). RLAY has less debt than DNLI: RLAY (33.3M) vs DNLI (44.4M). RLAY has higher revenues than DNLI: RLAY (8.36M) vs DNLI (0).
DNLIRLAYDNLI / RLAY
Capitalization3.29B1.55B213%
EBITDA-534.17M-322.8M165%
Gain YTD27.6805.437509%
P/E RatioN/AN/A-
Revenue08.36M-
Total Cash848M596M142%
Total Debt44.4M33.3M133%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRLAY
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
83%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
84%
Aroon
ODDS (%)
Bullish Trend 4 days ago
70%
Bearish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
RLAY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSCVX29.030.73
+2.58%
Nuveen Small Cap Value C
BREUX42.010.94
+2.29%
Baron Real Estate R6
CCTRX13.690.28
+2.09%
Columbia Sm Cp Val and Inflection R
JMVYX34.340.61
+1.81%
JPMorgan Mid Cap Value R6
PIEFX22.00N/A
N/A
Federated Hermes Emerging Markets Eq IS

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with NRIX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+5.29%
NRIX - DNLI
68%
Closely correlated
+5.64%
IMVT - DNLI
64%
Loosely correlated
+12.43%
VRDN - DNLI
63%
Loosely correlated
+0.27%
ARWR - DNLI
63%
Loosely correlated
-0.19%
SYRE - DNLI
62%
Loosely correlated
+6.62%
More

RLAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with NRIX. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLAY
1D Price
Change %
RLAY100%
+9.45%
NRIX - RLAY
61%
Loosely correlated
+5.64%
IMNM - RLAY
59%
Loosely correlated
+3.67%
RCUS - RLAY
55%
Loosely correlated
+4.99%
BDTX - RLAY
55%
Loosely correlated
+4.40%
DNLI - RLAY
54%
Loosely correlated
+5.29%
More